OCT Holdings Announces Rebrand, Unveils New Name and Logo

Pharmaceutical company OCT Holdings has announced a rebranding, adopting the new name “Octavian Therapeutics” along with an updated logo design.

The refresh is also being accompanied with the appointment of a new non-executive chair, and a fundraising initiative that is aimed at accelerating the British firm’s drug development efforts in the field of neuropathic pain treatment.

“The company has rebranded to Octavian Therapeutics – a name that underscores its commitment to pioneering life-changing treatments for patients with debilitating conditions,” says the Oxford-headquartered business.

“Our new brand, upcoming fundraise, and strong leadership team send a clear signal to investors: Octavian is ready for the next phase of growth,” adds the company’s CEO, Clarissa Sowemimo-Coker.

As a biotechnology start-up, Octavian Therapeutics focuses on creating prescription medications derived from cannabinoids, the natural compounds found in the cannabis plant.

Whereas previous research has focused on the more well known cannabinoids such as THC and CBD, scientists at Octavian Therapeutics are investigating hundreds of other minor cannabinoids that have barely been explored.

During the last six months, the company has specifically set its sights on producing non-addictive, small-molecule medicines that target the human endocannabinoid system (ECS) in order to alleviate chronic pain.

Source: Octavian Therapeutics